In a phase I/II clinical trial (15), a TCR gene targeting MAGE-A3 was transduced into T cells to treat metastatic melanoma, resulting in a response rate of 57% (4/7), with one patient achieving a complete response (CR) for 15 months, and three achieving a partial response (PR). Here, MAGEA3 is linked to metastatic melanoma.